Introduction And Strategic Context

Driving this expansion, the Global Nucleic Acid Therapeutics Contract Development and Manufacturing Organization (CDMO) Market anticipates significant growth from 2024 to 2030. This surge is fueled by breakthroughs in genetic medicine, escalating demand for personalized therapies, and a growing pipeline of nucleic acid-based drugs. Nucleic acid therapeutics, encompassing mRNA, siRNA, antisense oligonucleotides, and gene therapies, represent transformative approaches for treating a wide array of diseases, including genetic disorders, cancers, and infectious diseases.

 

As pharmaceutical and biotechnology firms increasingly concentrate on these complex therapies, the role of CDMOs becomes paramount. These specialized organizations provide crucial services, from process development to large-scale manufacturing, ensuring novel therapeutics meet rigorous regulatory standards and reach the market efficiently. The inherent complexity of nucleic acid therapeutics demands advanced manufacturing capabilities, stringent quality control, and adherence to evolving regulatory frameworks—areas where CDMOs offer indispensable expertise.

 

Market Size and Growth Projections

 

In 2024, the global nucleic acid therapeutics CDMO market is valued at approximately USD 16.3 billion. Projections indicate this market will reach around USD 40.1 billion by 2030, representing a compound annual growth rate (CAGR) of 15.4% over the forecast period.

 

Key Stakeholders

 

The market's ecosystem comprises a diverse set of stakeholders:

• Pharmaceutical and Biotechnology Companies: These entities, focused on researching and developing nucleic acid-based therapeutics, frequently partner with CDMOs to leverage specialized manufacturing expertise.

• CDMOs: These organizations specialize in the development and manufacturing of complex biologics, offering comprehensive solutions from process development to commercial-scale production.

• Regulatory Bodies: Agencies such as the FDA and EMA are critical in establishing guidelines and approving nucleic acid-based therapies, thereby influencing the operational standards for CDMOs.

• Investors and Venture Capitalists: Given the promising outlook for nucleic acid therapeutics, investment in CDMOs and biotech firms is increasing, driving innovation and capacity expansion.

• Healthcare Providers: Hospitals and clinics, as the ultimate users of these therapies, influence market dynamics and demand forecasting through their adoption rates.

Strategic Importance

 

The strategic relevance of the nucleic acid therapeutics CDMO market is amplified by several key factors:

• Technological Advancements: Innovations in delivery mechanisms, such as lipid nanoparticles for mRNA vaccines, have significantly broadened the therapeutic potential of nucleic acids.

• Regulatory Support: Accelerated approval pathways and orphan drug designations expedite the market entry for novel therapies, benefiting CDMOs involved in their production.

• Pandemic Response: The successful deployment of mRNA vaccines during the COVID-19 pandemic validated the efficacy of nucleic acid therapeutics, spurring increased investment and interest in this field.

• Personalized Medicine: The growing emphasis on individualized treatment regimens necessitates flexible and scalable manufacturing solutions, a niche effectively served by CDMOs.

In essence, the nucleic acid therapeutics CDMO market stands at the vanguard of a biotechnological revolution, providing solutions that address critical unmet medical needs through innovative therapies. The synergy between biotech firms and CDMOs is pivotal for translating scientific discoveries into accessible treatments, heralding a new era in personalized medicine.

Market Segmentation And Forecast Scope

The Global Nucleic Acid Therapeutics CDMO Market (2024–2030) can be segmented based on the type of nucleic acid, type of service, therapeutic area, end user, and region. These dimensions provide a multi-angle view of how contract development and manufacturing is evolving to support the rapidly advancing field of genetic medicine.

By Nucleic Acid Type

CDMOs are increasingly specializing in the production of different nucleic acid formats, each requiring unique expertise and infrastructure.

• mRNA

• siRNA (small interfering RNA)

• Antisense Oligonucleotides (ASOs)

• DNA Plasmids

• CRISPR-based Components (e.g., gRNA)

mRNA accounted for the largest share of the market in 2024, contributing to approximately 38% of total CDMO revenue, driven by post-COVID vaccine success and emerging applications in cancer and rare diseases.

Antisense oligonucleotides and siRNA are expected to witness the fastest growth, especially in neurodegenerative and cardiovascular indications, due to an expanding clinical pipeline.

 

By Service Type

CDMOs offer a wide range of services to nucleic acid drug developers, from concept to commercial launch:

• Process Development & Optimization

• Analytical Testing & Quality Control

• Clinical Manufacturing (GMP)

• Commercial Manufacturing

• Fill-Finish and Packaging Services

Commercial Manufacturing services will grow significantly during the forecast period, as more nucleic acid-based therapies move from clinical to late-stage and commercial approvals. Meanwhile, Process Development remains essential for emerging biotech firms without in-house capabilities.

 

By Therapeutic Area

Nucleic acid-based drugs are being investigated across a wide spectrum of diseases:

• Oncology

• Rare Genetic Disorders

• Infectious Diseases

• Cardiovascular Diseases

• Neurological Disorders

• Ophthalmic Diseases

Rare Genetic Disorders represent a high-growth niche due to orphan drug incentives, and require small batch, high-purity manufacturing—an area where CDMOs excel. Oncology remains the dominant revenue-generating segment.

 

By End User

• Large Biopharmaceutical Companies

• Small & Emerging Biotechs

• Academic Research Institutions

• Government and Military Labs

Small and Emerging Biotechs represent the most important client segment for CDMOs, making up an estimated 58% of the market in 2024. These companies often lack internal GMP facilities, creating sustained outsourcing demand.

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

North America currently dominates the market due to its mature biotech ecosystem and presence of advanced CDMO facilities. However, Asia-Pacific is emerging as a major outsourcing hub, thanks to government funding, lower production costs, and growing clinical trials infrastructure in countries like China, South Korea, and India.

 

Market Trends And Innovation Landscape

The Global Nucleic Acid Therapeutics CDMO Market is undergoing a transformation powered by deep scientific innovation, strategic collaborations, and scalable manufacturing solutions that cater to highly complex drug modalities. Between 2024 and 2030, several trends are reshaping the landscape—both in terms of technology adoption and operational capabilities within CDMOs.

1. Surge in mRNA and LNP Technology Platforms

The overwhelming success of mRNA-based COVID-19 vaccines has propelled lipid nanoparticle (LNP) technology into the spotlight. CDMOs are heavily investing in proprietary LNP platforms, aseptic fill-finish capabilities, and automated formulation systems to meet growing demand for oncology, infectious disease, and rare genetic therapy applications .

“Post-pandemic, LNP is no longer a niche – it’s the foundation of next-gen RNA therapeutics,” says a senior manufacturing strategist at an EU-based CDMO.

 

2. AI-Powered Process Optimization in GMP Suites

Artificial intelligence (AI) and machine learning (ML) tools are now being integrated into GMP environments for predictive batch control, real-time deviation alerts, and process yield improvement. CDMOs like Samsung Biologics and Thermo Fisher are exploring AI-powered PAT (Process Analytical Technology) to accelerate timelines while ensuring regulatory compliance.

AI is helping CDMOs reduce development cycles by up to 30%, according to internal case studies published by multiple biologic CDMOs.

 

3. Modular and Flexible Manufacturing Suites

As demand increases for small-batch, high-complexity nucleic acid therapies (especially antisense and siRNA), CDMOs are adopting modular cleanrooms and closed-system isolators that allow rapid switching between projects without cross-contamination.

The shift toward modularity is essential for enabling faster tech transfers and supporting clients with diverse modalities and small patient populations.

 

4. Partnerships with Biotech Startups and Academic Labs

To stay ahead, top-tier CDMOs are entering long-term strategic collaborations with emerging biotech startups and university spin-offs, providing process development, scale-up, and IND-enabling services. For example:

• Catalent partnered with Tiba Biotech for scalable RNA delivery platforms.

• WuXi Biologics launched incubator programs for gene therapy innovators in China and the U.S.

These alliances often result in joint IP filings, early access to novel payloads, and co-development of delivery systems.

 

5. Consolidation and M&A Activity

The CDMO space is seeing a wave of consolidation aimed at building end-to-end nucleic acid manufacturing ecosystems. Key M&A examples include:

• AGC Biologics acquiring MolMed for its gene and cell therapy infrastructure.

• Lonza’s expansion into oligonucleotide API manufacturing with multi-million-dollar facility upgrades in Visp, Switzerland.

This M&A trend is helping CDMOs evolve from service providers to strategic partners in the biotherapeutics value chain .

 

6. Emerging Focus on Personalized RNA Therapies

Beyond population-wide vaccines, the focus is shifting toward personalized nucleic acid drugs such as patient-specific cancer vaccines and tailored antisense therapies. CDMOs are scaling down equipment footprints and optimizing single-use bioreactor systems to address these niche needs.

 

Competitive Intelligence And Benchmarking

The Global Nucleic Acid Therapeutics CDMO Market is becoming increasingly competitive as demand for high-quality, scalable, and regulatory-compliant manufacturing services rises. This has drawn the attention of traditional CDMOs, biologics giants, and new entrants expanding into nucleic acid modalities. Below is a strategic overview of key players shaping the market.

1. Thermo Fisher Scientific

Thermo Fisher is a global leader in integrated CDMO services, with end-to-end capabilities spanning plasmid DNA, mRNA, and lipid nanoparticle (LNP) formulation. The company has invested in high-throughput RNA production platforms and has partnerships supporting mRNA vaccine development and RNA-based therapeutics. It also offers fill-finish and analytical services, positioning itself as a full-spectrum RNA CDMO .

• Strategic Focus : Vertical integration, tech platforms, global regulatory expertise

• Presence : North America, Europe, Asia

 

2. Catalent Inc.

Catalent has rapidly expanded its nucleic acid capacity with dedicated facilities for plasmid DNA and mRNA production. The company’s acquisition of Paragon Bioservices and investments in automated fill-finish lines bolster its role in early-to-late-stage RNA drug manufacturing. Catalent supports both clinical and commercial clients and has robust partnerships with biotech startups in oncology and genetic disorders.

• Strategic Focus : Tech transfer agility, modular GMP suites

• Presence : U.S., U.K., Belgium, Italy

 

3. AGC Biologics

AGC Biologics is a notable CDMO for antisense oligonucleotides (ASOs) and siRNA, providing API development, purification, and formulation services. Following its acquisition of MolMed, it has extended into gene therapy and rare disease therapeutics. AGC leverages custom oligonucleotide synthesis platforms to support complex molecules.

• Strategic Focus : Rare disease therapeutics, mid-scale batch capability

• Presence : Europe, Japan, U.S .

 

4. WuXi AppTec / WuXi Biologics

WuXi has become a preferred partner for global biopharma by offering one-stop solutions for DNA, RNA, and CRISPR components. The firm runs a global open-access platform and supports over 2,000 R&D projects annually. WuXi has been actively building facilities for oligonucleotide manufacturing and clinical-grade LNPs .

• Strategic Focus : High-throughput R&D, China-U.S. dual strategy

• Presence : China, U.S., Germany

 

5. Lonza Group

Lonza is investing heavily in expanding oligonucleotide and mRNA CDMO capacity, particularly at its Visp (Switzerland) and Portsmouth (U.S.) sites. Known for its strict regulatory compliance and biologics track record, Lonza offers upstream and downstream services tailored to high-purity nucleic acid APIs. It partners with mid- to large-size pharma firms and has been involved in platform technology innovation.

• Strategic Focus : End-to-end manufacturing for late-stage/commercial pipelines

• Presence : Global – strong European and U.S. base

 

6. BioSpring GmbH

BioSpring is a specialized CDMO for custom oligonucleotide manufacturing, especially for ASOs and gapmers. It is known for its expertise in quality control and delivery of high-complexity sequences with tight turnaround times. Though more niche, it is a key player in clinical-stage manufacturing for smaller biotech clients.

• Strategic Focus : Custom synthesis, ASO process scale-up

• Presence : Germany, EU

 

7. Rentschler Biopharma (via Rentschler ATMP)

Rentschler is actively expanding into nucleic acid manufacturing, including support for viral vectors and RNA payloads. While still emerging in the RNA CDMO space, it is strategically positioning itself through joint ventures in gene therapy and personalized RNA platforms.

• Strategic Focus : Personalized therapies, niche RNA biologics

• Presence : Germany, U.S.

 

Regional Landscape And Adoption Outlook

The regional dynamics of the Global Nucleic Acid Therapeutics CDMO Market are shaped by factors including the maturity of biotech ecosystems, regulatory infrastructure, manufacturing investments, and clinical research activity. While North America continues to dominate the landscape, Asia-Pacific is rapidly emerging as a high-growth outsourcing hub. Europe, Latin America, and parts of the Middle East are also gaining traction due to rising investments in biotech innovation.

North America: Mature Ecosystem with Innovation Leadership

North America—particularly the United States —commands the largest share of the global CDMO market for nucleic acid therapeutics. This is driven by:

• A robust pipeline of mRNA, ASO, and CRISPR-based drug candidates

• Strong funding for biotech startups and university spin-offs

• The presence of leading CDMOs such as Catalent , Thermo Fisher, and Lonza (U.S. sites)

• Proximity to regulatory authorities like the FDA, which expedites compliance processes

The U.S. alone accounts for over 40% of all global RNA and DNA therapy clinical trials, reflecting a deeply embedded culture of genetic R&D.

 

Europe: Specialized Capacity with Regulatory Strength

Europe represents a highly developed but somewhat segmented CDMO landscape. Countries like Germany, Switzerland, Belgium, and the UK host leading facilities focused on custom oligonucleotide synthesis, aseptic fill-finish, and rare disease therapeutics. Key CDMOs in this region include BioSpring GmbH, AGC Biologics (EU operations), and Rentschler Biopharma.

Europe is known for:

• Stringent but transparent regulatory frameworks (via EMA)

• A rising emphasis on personalized medicine and orphan drug development

• Regional funding initiatives under programs like Horizon Europe

Germany and Switzerland serve as powerhouses for high-purity manufacturing and personalized RNA therapy development.

 

Asia-Pacific: High-Growth Region with Expanding Infrastructure

Asia-Pacific is the fastest-growing region in the nucleic acid therapeutics CDMO market. Countries like China, South Korea, India, and Japan are heavily investing in GMP-compliant CDMO facilities, driven by:

• Lower production and labor costs

• Government incentives for biologics and ATMPs

• Expanding clinical trial ecosystems

• Increasing demand for localized manufacturing due to geopolitical shifts

China in particular is a hub for WuXi Biologics, while India is seeing growth in domestic and export-oriented CDMO services, including oligonucleotide APIs and CRISPR tools .

Asia-Pacific CDMOs are quickly becoming global outsourcing alternatives to U.S./EU-based facilities.

 

Latin America and Middle East & Africa (LAMEA): Emerging with Gaps

While LAMEA regions contribute a relatively smaller share, Brazil, Saudi Arabia, and the UAE are investing in biotech manufacturing and infrastructure. However, challenges remain:

• Limited CDMO capacity specific to nucleic acid therapeutics

• Regulatory delays and workforce limitations

• Heavy reliance on imports for advanced biologics and oligo therapies

Still, the region represents a long-term opportunity for CDMOs willing to invest in technology transfer, training, and government partnerships.

 

End-User Dynamics And Use Case

The demand for CDMO services in the nucleic acid therapeutics market is primarily driven by the needs of varied stakeholders across the biopharmaceutical ecosystem. Each end user group brings unique requirements in terms of scalability, regulatory support, and technological capabilities. Understanding these dynamics is critical to identifying high-growth service opportunities.

1. Small & Emerging Biotech Companies

Startups and mid-sized biotechs constitute the largest client base for CDMOs in the nucleic acid space. Lacking in-house manufacturing capabilities, these companies rely heavily on CDMOs for:

• Preclinical and IND-enabling studies

• Clinical trial material (CTM) production

• Regulatory documentation support

• Formulation and fill-finish services

These clients often seek speed, flexibility, and access to regulatory know-how, which makes CDMOs indispensable partners throughout the R&D-to-launch cycle.

In 2024, small and emerging biotechs are estimated to contribute over 58% of global CDMO revenue for nucleic acid therapeutics.

 

2. Large Biopharmaceutical Companies

Large pharma companies are expanding their nucleic acid portfolios, often via partnerships or licensing deals. While some have internal GMP facilities, many prefer outsourcing complex or early-stage RNA and ASO production to experienced CDMOs to:

• Mitigate risk

• Manage costs

• Scale based on real-time demand

These clients require global quality standards, robust supply chain logistics, and multi-regional regulatory support. Lonza, Catalent, and Thermo Fisher are preferred vendors for such partnerships.

 

3. Academic and Research Institutions

Universities, translational research centers, and hospitals developing experimental RNA/CRISPR therapeutics increasingly partner with CDMOs for:

• Feasibility studies

• Pilot-scale GMP manufacturing

• Support in transitioning to clinical trials

These end users often seek customizable, modular manufacturing support and benefit from CDMOs with rapid prototyping capabilities.

 

4. Government and Military Health Initiatives

Post-COVID, several governments have invested in domestic mRNA manufacturing capabilities to bolster pandemic preparedness. CDMOs are engaging in:

• Public-private partnerships

• Onshore tech transfer agreements

• Supply contracts for emergency stockpiling

In the U.S., BARDA-funded mRNA infrastructure partnerships (e.g., with Thermo Fisher and Resilience) reflect this trend.

 

Representative Use Case

A tertiary oncology research hospital in South Korea collaborated with a global CDMO to manufacture personalized mRNA-based cancer vaccines for a Phase I clinical trial. The hospital lacked GMP facilities, so the CDMO provided:

• LNP formulation and aseptic fill-finish

• Regulatory-compliant batch records

• Analytical QC services

This collaboration reduced the lead time to first-patient-in (FPI) by 40% and enabled seamless IND filing with the MFDS (Korean FDA), accelerating trial execution.

 

Recent Developments + Opportunities & Restraints

Recent Developments (2023–2025)

• Thermo Fisher Scientific and Moderna Expand mRNA Manufacturing Collaboration
  In early 2024, Thermo Fisher Scientific announced an expansion of its strategic collaboration with Moderna to scale up mRNA manufacturing capabilities, aiming to meet the growing global demand for mRNA-based therapeutics.

• WuXi AppTec Opens New Oligonucleotide Manufacturing Facility in China
  In mid-2023, WuXi AppTec inaugurated a state-of-the-art oligonucleotide manufacturing facility in China, enhancing its capacity to support the development and production of nucleic acid therapeutics.

• Lonza Invests in Plasmid DNA Manufacturing Expansion in Switzerland

• In late 2023, Lonza announced a significant investment to expand its plasmid DNA manufacturing capabilities at its Visp, Switzerland site, aiming to support the growing demand for gene therapies and vaccines.

• Catalent Acquires Delphi Genetics to Enhance Gene Therapy Capabilities
  In 2024, Catalent completed the acquisition of Delphi Genetics, a Belgian plasmid DNA manufacturer, to bolster its gene therapy development and manufacturing services.

• AGC Biologics Partners with Adaptive Biotechnologies for TCR Therapeutics
  In 2023, AGC Biologics entered into a partnership with Adaptive Biotechnologies to develop and manufacture T-cell receptor (TCR) therapeutics, expanding its footprint in the nucleic acid therapeutics CDMO market.

 

Opportunities

• Rising Demand for Personalized Medicine
  The increasing focus on personalized medicine is driving demand for nucleic acid therapeutics, as these therapies can be tailored to individual genetic profiles, offering more effective treatment options.

• Advancements in Gene Editing Technologies
  Technological advancements in gene editing tools, such as CRISPR-Cas9, are expanding the possibilities for nucleic acid therapeutics, creating new opportunities for CDMOs specializing in these areas.

• Expansion into Emerging Markets
  Emerging markets, particularly in Asia-Pacific and Latin America, present significant growth opportunities for CDMOs due to increasing investments in biotechnology infrastructure and favorable regulatory environments.

 

Restraints

• Complex Regulatory Landscape
  Navigating the complex and evolving regulatory requirements for nucleic acid therapeutics across different regions can pose challenges for CDMOs, potentially leading to delays in product development and approval.

• High Manufacturing Costs
  The production of nucleic acid therapeutics involves sophisticated technologies and stringent quality controls, resulting in high manufacturing costs that can be a barrier for smaller companies and limit market accessibility.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size in 2024	USD 16.3 Billion
Revenue Forecast in 2030	USD 40.1 Billion
Overall Growth Rate (CAGR)	15.4% (2024 – 2030)
Base Year for Estimation	2024
Historical Data Range	2019 – 2023
Unit of Measurement	USD Million, CAGR (%)
Segmentation	By Nucleic Acid Type, Service Type, Therapeutic Area, End-User, Geography
By Nucleic Acid Type	mRNA, siRNA, Antisense Oligonucleotides, DNA Plasmids, CRISPR
By Service Type	Process Development, Analytical Testing, Clinical Manufacturing, Commercial Manufacturing, Fill-Finish
By Therapeutic Area	Oncology, Rare Diseases, Infectious Diseases, Neurological Disorders
By End-User	Small Biotechs, Large Pharma, Academia, Government
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Germany, China, India, Japan, South Korea, Brazil, UAE, etc.
Market Drivers	• Rise in mRNA-based pipelines • Outsourcing by early-stage biotechs • AI and modular CDMO tech adoption
Customization Option	Available upon request